CombiChem Inc. appoints William A. Scott to its board of directors.SAN DIEGO--(BW HealthWire)--Feb. 17, 1997--CombiChem Inc. has announced the appointment of William A. Scott, Ph.D., to its board of directors. Scott was most recently senior vice president, drug discovery research, at Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Pharmaceutical Research Institute. CombiChem accelerates drug discovery through the integration of medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. and small library design technology. ``Because of the technological and scientific progress CombiChem has made in the past year, we are now bringing individuals to our board, like Bill Scott, who can provide guidance and expertise in the drug discovery process,'' said Vicente Anido Jr., Ph.D., chief executive officer and president of CombiChem. Pierre Lamond, chairman of CombiChem's board of directors and general partner of Sequoia Capital, said: ``We welcome Dr. Scott to the board of CombiChem. He brings over 25 years of experience in the pharmaceutical industry, knowledge of chemistry and contacts in the drug discovery arena.'' The CombiChem board of directors also includes Anido; Peter Myers, Ph.D., chief scientific officer and chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. at CombiChem; Philippe Chambon of the Sprout Group; Terry Gould of Brinson Partners; and Robert Jaffe of Sorrento Associates. Scott received his Ph.D. in biochemistry from the California Institute of Technology California Institute of Technology, at Pasadena, Calif.; originally for men, became coeducational in 1970; founded 1891 as Throop Polytechnic Institute; called Throop College of Technology, 1913–20. in 1967. Scott is currently a member of six boards of directors, including those of the National Neurofibromatosis Neurofibromatosis Definition Neurofibromatosis (NF), or von Recklinghausen disease, is a genetic disease in which patients develop multiple soft tumors (neurofibromas). These tumors occur under the skin and throughout the nervous system. Society, the Biotechnology Processing Center at MIT MIT - Massachusetts Institute of Technology and the Scientific Advisory Board of Rider College. He is also an adjunct professor at Rockefeller University in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , a position he has held since 1983. Scott has a proven track record in multiple areas of corporate management. While at Bristol-Myers Squibb, Scott was responsible for the overall scientific direction of the drug discovery and basic research programs for the Pharmaceutical Group. The Group, spread out over five locations in the United States and Canada, conducted research in such areas as cardiovascular diseases, CNS See Continuous net settlement. CNS See continuous net settlement (CNS). diseases and infectious diseases. Under Scott's guidance, the Group submitted more than 70 new chemical entities for development as new therapeutic agents between 1991 and 1996. He also masterminded major alliances with biotech companies and academic institutions such as Massachusetts General Hospital Massachusetts General Hospital Health care The major teaching hospital for Harvard Medical School, widely regarded as one of the best health care centers in the world and the Garvin Institute in Sydney, Australia. CombiChem's mission is to offer a unique approach to accelerated drug discovery. The company works in partnership with pharmaceutical and biotechnology corporations that provide biological capabilities, while CombiChem provides the chemical expertise in the discovery process. ``The three ways we work with our partners are lead generation, lead evolution and lead optimization,'' said Anido. ``The reason we're able to address all three areas is that we've built a paradigm we call the CombiChem Drug Discovery Engine. It represents a synergy between our medicinal chemistry expertise and our small library design technology, giving us a unique, iterative approach. In fact, this synergy is the foundation for all our efforts.'' CombiChem, founded in 1994, is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. with international headquarters in San Diego. CONTACT: CombiChem Inc., San Diego Vicente Anido, 619/530-0484 or Friestedt International, San Diego Susanne Friestedt, 619/223-8844 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion